Sight Sciences (SGHT) to Expand in Europe With New Launch

Sight Sciences, Inc. SGHT has made significant progress in bolstering its presence in the European eye surgery market with the launch of the Ergo-Series of the OMNI Surgical System. This advanced technology is designed to facilitate minimally invasive glaucoma procedures.

With this development, the company expects to advance in the promising field of surgical interventions for adults with open-angle glaucoma across the continent.

Enhanced Ergonomics and Precise Access

The Ergo-Series, initially introduced in the United States in March 2023, has garnered widespread acclaim among surgeons for its improved ergonomics and optimized cannula tip. These enhancements allow for gentler and more precise access to Schlemm’s canal, a crucial aspect of glaucoma surgery. By streamlining the surgical process and offering improved handling, the Ergo-Series empowers surgeons to perform procedures with greater confidence and efficacy.

Strategic Implication

The launch of the Ergo-Series in Europe marks a strategic move for Sight Sciences to expand its foothold in the region. By tapping into the European market, Sight Sciences aims to capitalize on the growing demand for advanced eye care technologies.

Positive feedback from surgeons further underscores the potential impact of the Ergo-Series in Europe. A spokesperson from Bürgerhospital Eye Clinic in Frankfurt commended the improved ergonomics and design enhancements, highlighting the potential for earlier interventions and better disease management. Further, a consultant ophthalmic surgeon at Princess Alexandra Eye Pavilion in Edinburgh and NHS Research Scotland Clinical Lead for Ophthalmology has also praised the intuitive design and enhanced tactile feedback, emphasizing the device's accessibility across various stages of glaucoma treatment.

Zacks Investment Research
Image Source: Zacks Investment Research


Market Prospects

According to a Grand View Research report, the global glaucoma surgery devices market is poised for robust growth by 2030 with a projected CAGR of 4.61%. Key drivers include the aging population, increased surgical adoption for glaucoma and government initiatives for eye care. Lifestyle changes, notably diabetes and hypertension, contribute to visual impairments, fueling demand for surgical interventions.

Share Price Performance

Over the past year, shares of SGHT have plunged 63.4% against the industry’s 9.3% rise.

Zacks Rank and Other Key Picks

Sight Sciences carries a Zacks Rank #2 (Buy) currently.

A few other top-ranked stocks in the broader medical space are DaVita DVA, Cardinal Health CAH and Stryker SYK. While DaVita presently sports a Zacks Rank #1 (Strong Buy), Cardinal Health and Stryker carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Estimates for DaVita’s 2024 earnings per share have moved up from $8.46 to $8.86 in the past 30 days. Shares of the company have increased 45.6% in the past year compared with the industry’s 7.9% rise.

DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. In the last reported quarter, it delivered an earnings surprise of 22.2%.

Cardinal Health’s stock has increased 32.6% in the past year. Earnings estimates for Cardinal Health have risen from $6.90 to $7.17 for fiscal 2024 and from $7.73 to $7.94 for fiscal 2025 in the past 30 days.

CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.7%.

Estimates for Stryker’s 2024 earnings per share have increased from $11.54 to $11.84 in the past 30 days. Shares of the company have moved 32.8% upward in the past year compared with the industry’s rise of 4.9%.

SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an earnings surprise of 5.8%.

Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Stryker Corporation (SYK) : Free Stock Analysis Report

DaVita Inc. (DVA) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Sight Sciences, Inc. (SGHT) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.